Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
progression or deaths (PFS) | 0.65 [0.48, 0.88] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | important | - |
objective responses (ORR) | 1.68 [1.05, 2.68] | | > 1 | | 0% | 1 study (1/-) | 98.5 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE leading to death (grade 5) | 1.55 [0.26, 9.42] | | < 1 | | 0% | 1 study (1/-) | 31.7 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.87 [0.51, 1.47] | | < 1 | | 0% | 1 study (1/-) | 70.3 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.70 [0.40, 1.21] | | < 1 | | 0% | 1 study (1/-) | 89.7 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 2.06 [0.07, 61.91] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 0.75 [0.39, 1.43] | | < 1 | | 0% | 1 study (1/-) | 81.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 2.06 [0.07, 61.91] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |
Acute kidney injury TRAE (grade 3-4) | 4.15 [0.19, 92.82] | | < 1 | | 0% | 1 study (1/-) | 18.8 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 1.03 [0.06, 16.58] | | < 1 | | 0% | 1 study (1/-) | 49.3 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 0.51 [0.02, 15.37] | | < 1 | | 0% | 1 study (1/-) | 64.8 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 1.03 [0.02, 52.11] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 4.15 [0.19, 92.82] | | < 1 | | 0% | 1 study (1/-) | 18.8 % | NA | not evaluable | | non important | - |
Eczema TRAE (grade 3-4) | 0.51 [0.02, 15.37] | | < 1 | | 0% | 1 study (1/-) | 64.8 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 1.03 [0.02, 52.11] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.51 [0.02, 15.37] | | < 1 | | 0% | 1 study (1/-) | 64.8 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 1.03 [0.02, 52.11] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 1.03 [0.02, 52.11] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 0.51 [0.02, 15.37] | | < 1 | | 0% | 1 study (1/-) | 64.8 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 0.51 [0.02, 15.37] | | < 1 | | 0% | 1 study (1/-) | 64.8 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.17 [0.01, 3.39] | | < 1 | | 0% | 1 study (1/-) | 87.5 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.17 [0.01, 3.39] | | < 1 | | 0% | 1 study (1/-) | 87.5 % | NA | not evaluable | | non important | - |
Myocarditis TRAE (grade 3-4) | 2.06 [0.07, 61.91] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 1.03 [0.02, 52.11] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Nephritis TRAE (grade 3-4) | 2.06 [0.07, 61.91] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.27 [0.07, 0.97] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
Paraesthesia TRAE (grade 3-4) | 0.25 [0.01, 5.69] | | < 1 | | 0% | 1 study (1/-) | 80.3 % | NA | not evaluable | | non important | - |
Pneumonia TRAE (grade 3-4) | 1.03 [0.14, 7.39] | | < 1 | | 0% | 1 study (1/-) | 48.9 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 6.38 [0.76, 53.66] | | < 1 | | 0% | 1 study (1/-) | 4.5 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 1.03 [0.02, 52.11] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 2.06 [0.07, 61.91] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 1.03 [0.02, 52.11] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 4.15 [0.19, 92.82] | | < 1 | | 0% | 1 study (1/-) | 18.8 % | NA | not evaluable | | non important | - |
Urticaria TRAE (grade 3-4) | 2.06 [0.07, 61.91] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 2.06 [0.07, 61.91] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |